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Massachusetts Life Sciences Center grant 
to increase clinical trials at Baystate Health
Baystate Medical 
Center has been awarded 
$3,949,912 in grant fund-
ing from the Massachu-
setts Life Sciences Center 
(MLSC) in an extremely 
competitive program 
designed to sustain the 
Commonwealth’s com-
petitive edge in advancing 
human health. 
“This support will 
expand our capacity to 
perform efficient and 
compliant clinical trials by 
building a Clinical Trials 
Unit (CTU) at Baystate 
Medical Center and 
make novel treatments 
available to our diverse 
patient population. We 
are grateful to MLSC, our 
legislators, the Governor, 
and the citizens of the 
Commonwealth for this 
investment in the future 
of biomedical research in 
western Massachusetts,” 
says Dr. Peter Friedmann, 
Chief Research Officer for 
Baystate Health and Asso-
ciate Dean for Research 
at UMMS-Baystate. “For 
Baystate Health and 
UMMS-Baystate, it is an 
opportunity to increase 
access to innovative treat-
ments for the patients and 
communities we serve, 
engage faculty and staff in 
impactful clinical research, 
expand collaborations with 
academic and industry 
partners, and improve the 
productivity and efficiency 
with which we conduct 
clinical trials.”
Baystate is among 
11 hospitals, colleges 
and other institutions to 
receive a total of $30.95 
million in capital grant 
funding to support the 
state’s global leader-
ship in the life sciences 
sector. There were 45 
applications. The fund-
ing, provided through 
the MLSC’s Competi-
tive Capital Program, is 
designed to support 
advances in human health, 
accelerate innovation in 
the areas of clinical and 
translational research, and 
expand the capacity of 
life sciences development 
and job growth across the 
Commonwealth.  
“The grant will expand 
local capacity to perform 
clinical trials of new inno-
vations in digital health 
and medical devices right 
here in Springfield. We 
know that Massachusetts 
is a national leader in 
health sciences, and 
western Massachusetts 
is no exception, with 
new research happen-
ing at places like UMass 
Amherst, and advances in 
treatment happening regu-
larly at Baystate Medical 
Center, which makes this 
new partnership so excit-
ing. This will benefit the 
entire Massachusetts life 
sciences system and keep 
western Massachusetts on 
the map in this critical and 
growing field,” says State 
Senator Eric Lesser, who 
worked to pass the Mass 
Life Sciences Bill, which 
funded this grant program. 
Baystate has long part-
nered with the Center for 
Clinical and Translational 
Science (CCTS) at UMMS-
Worcester, Pioneer 
Valley Life Sciences 
Institute and the Institute 
for Applied Life Sciences 
at UMass Amherst in the 
Center for Clinical and 
Translational Investigation, 
and the Clinical and Trans-
lational Science Institute at 
Tufts to promote trans-
lational research in the 
western part of the state. 
Baystate’s Clinical Trials 
Office (CTO) was launched 
in 2018 to build upon 
these research partner-
ships, as well as relations 
with industry sponsors 
to conduct innovative 
translational research and 
L to R: State Sen. James Welch; Jane Albert, Senior Vice President of Marketing, Communications & External Relations, Baystate Health; John 
Maybury, Chairman of the Board of Trustees, Baystate Health; State Rep. Carlos Gonzalez, State Sen. Eric Lesser; Travis McCready, President of 
MLSC; State Rep. Brian Ashe; Dr. Mark Keroack, President and CEO of Baystate Health; Dr. Peter Friedmann, Chief Research Officer, Baystate 
Health; State Rep. Joseph Wagner; Nancy Shendell-Falik, President of Baystate Medical Center; State Rep. Michael Finn; and Jean Ahn, Senior Vice 
President and Chief Strategy Officer, Baystate Health.
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TAVR research brings innovative, life-
saving heart procedure to Baystate
Aortic valve stenosis is a condition 
where the heart’s aortic valve begins 
to shrink, limiting blood flow from the 
heart to the rest of the body. The most 
common cause is the wearing down 
of the valve due to age, like how your 
car brakes wear down over time. This 
process can lead to symptoms like short-
ness of breath and dizziness. You would 
think that heart surgery is the automatic 
solution, but for some patients, it is too 
risky. A patient may be too old or frail to 
be put under for surgery and recuperate 
later on.
“Unfortunately, untreated aortic 
valve disease is fatal. After the onset of 
symptoms, the survival rate is as low as 
50% at 2 years,” says Grace Lavalley, 
DNP, AGACNP-BC, a cardiology nurse 
practitioner. “The definitive treatment 
for aortic valve stenosis has been valve 
replacement surgery.” With regular aortic 
valve replacement (AVR), the patient is 
sedated and the chest is cut open. The 
heart is stopped and an artificial unit is 
used to pump the blood. The faulty valve 
is surgically removed and replaced with 
a new one. A patient may be in the ICU 
for days after this surgery, and the chest 
could take up to two months to heal 
completely. This intensive surgery now 
has a simpler solution with TAVR (Trans-
catheter Aortic Valve Replacement), 
a minimally-invasive valve procedure. 
A patient has to be referred by their 
primary care provider or cardiologist to 
receive TAVR.
“If AVR surgery is not an option, TAVR 
is a fantastic alternative for those who 
may be considered intermediate to high 
risk for surgery,” adds Lavalley. TAVR 
was first implemented in in-operable or 
high-risk patients for surgery; indications 
have since expanded to intermediate 
risk. Baystate will see further expan-
sion of indications to lower-risk patients 
based on current low-risk trials done 
in the United States. Interventional 
cardiologist Ashequl Islam, MD was a 
part of the cardiac team that brought 
TAVR to Baystate and has studied its 
effectiveness. 
“We are excited to offer TAVR to the 
very large patient population which we 
serve,” he says. Results of nationwide 
clinical trials for TAVR have shown better 
or equivalent results compared to open 
heart surgery. With TAVR, patients do 
not undergo bypass, most have minimal 
sedation, and their length of stay is 
significantly reduced with no need for 
intensive care. Patients are more alert 
and awake and can be back on their 
feet within hours. 
To perform TAVR in majority of 
patients, a small puncture is made in the 
groin area and a catheter with the new 
valve is inserted into the diseased valve, 
diminishing the need for external pumps 
to keep the heart and lungs work-
ing. The new valve is embedded and 
anchored in the existing valve, giving it 
new life. After the catheter is pulled out, 
the entry site is stitched up.
“TAVR is one of those revolutionary 
procedures that has really changed the 
world of cardiac care,” adds Dr. Islam. 
“A lot of patients couldn’t get treat-
ment before this. Baystate is the only 
advanced heart and vascular hospital in 
western Massachusetts and this allows 
us to deliver state-of-the art, high quality 
care. Cardiac patients would have to go 
out of the Baystate network if not for this 
type of procedure.” The cardiology team 
has expanded from TAVR to other valve 
procedures and treatments, including 
catheter-based mitral valve repair. They 
are also involved in clinical trials to 
investigate non-surgical treatment meth-
ods for other heart valve conditions.
“We are always looking at new and 
innovative ways to deliver the best heart 
care to our patients,” concludes Dr. 
Islam. 
For more information on Baystate’s 
Heart and Vascular program, visit bay-
statehealth.org/services/heart-vascular.
(Continued from page 1)
high-impact clinical trials. 
Among the many proj-
ect objectives – which 
are also funded in part 
by a $550,000 commit-
ment from BH in 2019 to 
develop the Clinical Trials 
Unit – are to: 
• Create a physical outpa-
tient CTU and outpatient 
research pharmacy at 
3300 Main St. in Spring-
field and a satellite unit at 
Baystate Franklin Medical 
Center in Greenfield. 
• Refurbish space in 
BMC’s 3601 Main Street 
building in Springfield 
to provide cubicle and 
office space for clinical 
research personnel and 
interns.
• Work with local commu-
nity colleges to develop 
internships and programs 
to ensure a trained work-
force in clinical research, 
including the creation of 
a Certificate in Clinical 
Research. 
“We will work with 
the life sciences degree 
programs at STCC, HCC, 
and Greenfield Commu-
nity College to facilitate 
training and workforce 
development from which 
we can recruit and train 
qualified research staff,” 
adds Dr. Friedmann. “We 
believe we can achieve a 
five-fold increase in active 
clinical trials throughout 
Baystate Health by 2023, 
speeding the human test-
ing of these innovative 
medications, devices, and 
digital health products.”  
Research & Education Celebration 
held on May 15, 2019
Timothy Mader, MD, receives the 
Excellence in Research Mentoring 
Award from Dr. Friedmann and 
Jenn Pacheco, MPH, CIM, CIP.
Mihaela Stefan, MD, PhD, is the 
recipient of the Research Transla-
tion Award.
Laura Gebhardt receives the 
Award for Outstanding Clinical 
Research Support.
Lili Peacock-Chambers, MD, 
MSc, receives the Early Career 
Investigator Award from Dr. Peter 
Lindenauer.
Members of the Baystate cardiology team: (L to R) Noel Harrington, Ashequl Islam, MD, and Grace Lavalley, 
DNP, AGACNP-BC. 
(Above and below) Attendees 
gather around the posters at the 
Poster Session.
An attendee reads the last issue 
of The Innovator. 
Attendees stop for a photo.
Dr. Tara Lagu speaks during one 
of the day’s panel discussions.
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Baystate’s new ovarian tissue registry: a team effort
The ovarian tissue 
registry at Baystate began 
at the end of 2018 as a 
collaboration among Drs. 
Sallie Schneider (Direc-
tor of the Biospecimen 
Resource and Molecular 
Analysis Facility; Pioneer 
Valley Life Sciences 
Institute), Tashanna Myers 
(Gynecologic Oncology), 
and Christopher Otis (Ana-
tomic Pathology). Their 
goal is to collect samples 
of ovarian tissue from 
consenting patients as 
part of a research registry.  
The ovarian tissue registry 
is modeled after the 
successful Rays of Hope 
Breast Tissue Registry at 
Baystate. 
“In breast cancer, it is 
often difficult to get tumor 
tissue because the tumors 
are usually very small 
when first detected and 
the margins are important 
for diagnosis,” explains 
Dr. Schneider. “Ovarian 
cancer is usually found too 
late, and at this point the 
tumors are very large.” 
Patients who are 
already undergoing 
surgery to remove part 
of or the entire ovary are 
approached by surgeons 
in the hospital to see if 
they’d like to contribute to 
the ovarian tissue registry. 
To participate, the patient 
must be an adult, must 
be able to give their own 
consent, and must have 
a scheduled surgery 
where an ovary is being 
removed. Surgeons will 
send tumor tissue (such 
as an ovarian mass) to the 
pathologist who exam-
ines the specimen and 
chooses tumor tissue to 
submit to the tissue bank. 
Lynn Eaton, MT (ASCP), 
CCRP, Senior Clinical 
Research Coordinator, is 
the individual who ensures 
the entire procedure runs 
smoothly from start to 
finish.  
“Although we come 
from different depart-
ments, we all work 
together as a team,” Eaton 
says. “It’s a very collabora-
tive process involving the 
surgeon’s staff assistant, 
the pre-admission chart 
room, the surgeon and 
surgery personnel, PVLSI 
staff, pathology administra-
tive staff, and the patholo-
gists.” Dr. Christopher Otis, 
who oversees the pro-
curement of the collected 
tissue, makes sure it is 
handled appropriately as it 
is put into the registry. Dr. 
Esma Ersoy, a pathology 
resident, is also involved 
in this process since she 
has a particular interest in 
a specific protein (HER2) 
found within ovarian 
tumors.  
“Once the tumor cells 
are collected, the next 
step is to understand their 
characteristics.” says Dr. 
Ersoy. “We ask things like 
‘What stage is this tumor 
in? Are the cells resistant 
to chemotherapy? What 
kind of targetable proteins 
(e.g. HER2) are involved in 
the tumorigenesis? Are the 
cells resistant to chemo-
therapy?’” Since there are 
so many different types 
of cancers and variations 
of cancer cells, extensive 
research is necessary to 
work toward finding effec-
tive treatments.  
“In the era of preci-
sion medicine, we know 
that cancer cells can be 
diverse,” explains Dr. 
Myers. “Standard che-
motherapy will not be 
sufficient to finding a cure 
for this disease. Studying 
individual tissue samples 
will be key to answering 
questions about ovarian 
cancer.” As of May 2019, 
over 20 ovarian tissue 
samples have been col-
lected.  
“As the registry grows, 
we will see more peaks 
of abnormalities and 
averages,” adds Dr. Otis. 
“We will learn more about 
the disease and offer/
develop new treatments 
to be delivered to the 
bedside. This is important 
translational research.” 
Many patients who are 
approached by Dr. Myers 
and her team are eager 
and excited to participate 
in the ovarian tissue bank. 
“Patients have been 
selfless and want to help 
others who might be 
experiencing the same 
issues,” explains Dr. Myers. 
“The tissue we collect is 
impactful beyond that one 
single patient. We want 
to change the course of 
ovarian cancer treatment 
and figure out the causes.” 
The hope is that this 
research will answer ques-
tions about ovarian cancer 
in the future and why 
ovarian cells can become 
cancerous. 
“Through this research, 
we are creating something 
meaningful for years to 
come,” concludes Dr. 
Ersoy. “It’s being part of 
a bigger picture. With 
Baystate becoming more 
of an academic institu-
tion, research like this 
is important for us to 
grow and strengthen our 
knowledge.”
THE PROCESS OF THE OVARIAN TISSUE REGISTRY
#1 Dr. Tashanna Myers: Asks a patient for consent to 
participate in ovarian tissue registry.
#2 Lynn Eaton, MT (ASCP), CCRP: Alerted that the tissue 
will be collected, enrolls the patient into the database and 
gets all remaining parts in place.
#3 Tissue is collected at time of surgery.
#4 Dr. Christopher Otis: Oversees proper procurement of 
collected tissue.
#5 Dr. Sallie Schneider: Receives the tissue and 
coordinates the processing for the tissue bank. Ensures 
tissue is available in multiple forms for research purposes.
#6 Dr. Esma Ersoy: One of the many residents who will be 
researching the ovarian tissue.
The ovarian tissue registry team at Baystate Health: (L to R) Christopher Otis, MD, Tashanna Myers, MD, Sallie 
Schneider, PhD, Lynn Eaton, MT (ASCP), CCRP, and Esma Ersoy, MD.
Baystate Health was ranked the 14th (of 74) best Massachusetts 
employer through a study conducted by Forbes partnering with market 
research company Statista. The goal was to identify organizations 
liked best by employees in Forbe’s first-ever ranking of America’s best 
employers by state. The list was compiled through an anonymous 
survey of 80,000 Americans nationally working for businesses with at 
least 500 employees. On a scale of zero to 10, participants rated how 
likely they’d be to recommend their employer to others. The final list 
ranks 1,430 employers which received the most recommendations in 
each of the 50 states and the District of Columbia.
Baystate Health named a top MA employer!
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We are interested in ensuring that Baystate employees and patients (and their 
families) are aware of the important research that goes on at Baystate and how it 
contributes to better patient care. The Innovator welcomes feedback and story 
ideas. Contact Allison Litera at allison.litera@baystatehealth.org to submit yours.
Meet the Researcher Research Training for Fellows and Junior Faculty
Training the next generation of 
healthcare researchers is a priority for 
UMMS-Baystate, and a major focus for 
our Institute for Healthcare Delivery and 
Population Science (IHDPS). Thanks 
to our affiliations with the Clinical and 
Translational Science Awards at UMMS 
and Tufts, our trainees and faculty can 
develop skills to expand the critical 
mass of expert scientists in clinical and 
translational research through innova-
tive education, training, and mentoring 
programs. 
For junior faculty, career development 
awards go by a “K” designation; both 
Tufts and UMass sponsor institutional 
KL-2s, while UMass sponsors the K-12. 
These highly competitive awards will 
fund up to 75% effort to train in research 
and perform a mentored research proj-
ect over 2-3 years. In addition to these 
mentored career development grants, 
fellowships and forums for junior faculty 
are available as well. 
 A K-12 from the University of Mas-
sachusetts Medical School and its Mas-
sachusetts Consortium for Cardiopulmo-
nary Implementation Science currently 
supports IHDPS fellow Lauren Westafer, 
DO, MPH, MS, Assistant Professor in the 
Department of Emergency Medicine, 
to gain expertise in implementation 
science, as well as to develop and test 
strategies for moving evidence into 
routine practice.
“My grant enables me to study 
provider decision-making in the 
diagnostic evaluation of pulmonary 
embolism. What we're seeing is that 
providers are overtesting patients for 
this disease process, despite guidelines 
and evidence-based algorithms. I'm 
working to figure out – ‘how do we get 
providers to use these tools for more 
rational testing?’ The grant is giving me 
an invaluable opportunity to work on 
this project, take classes, conduct other 
projects, and receive amazing mentor-
ship from top researchers to build skills 
as a clinician-investigator.” 
The KL-2, available both from Tufts 
Clinical and Translational Science 
Institute (CTSI) and the UMMS Center 
for Clinical and Translational Sciences, is 
another mentored career development 
award with a broad focus on transla-
tional science. Lili Peacock-Chambers, 
MD, MSc, Assistant Professor in the 
Department of Pediatrics and Fellow 
in the IHDPS, has a KL-2 through Tufts 
focused on developing tools to help 
mothers with opioid addiction and to 
take better care of their children.
“My KL-2 is focused on adapting 
and integrating an evidence-based 
parenting intervention for mothers in 
recovery from opioid use disorders into 
Early Intervention child development 
services. We have conducted nearly 30 
mothers in recovery and 25 community 
stakeholders to inform the adaptation of 
our intervention. In addition we formed 
an advisory panel to guide our work. 
We are in the process of deploying our 
newly adapted training and intervention 
the summer of 2019. I have personally 
advanced my training in qualitative 
and community-engaged research and 
received excellent support in both grant 
and manuscript writing.”
Training grants for post-docs 
(residents and fellows) have a “T” 
designation. These are 2-year training 
programs that provide salary support 
with expectation that the trainee spends 
75% of their time engaged in research. 
There are no Baystate post-docs in the 
T program at this time. Through both 
the T and K grants, trainees have the 
opportunity to pursue research under 
a team of mentors and to pursue and 
complete a Master’s degree in clinical/
translational research. These training 
grants provide outstanding opportuni-
ties for residents and fellows who wish 
to take time to develop research skills.  
Both UMMS CCTS and Tufts CTSI 
offer a wide array of courses, work-
shops, and seminars in topics such 
as clinical and translational research, 
career development, grant writing, 
quality improvement, and regulatory 
affairs. They also have mentoring sup-
port grants, fellowships, and a forum 
for junior faculty. To learn more, visit 
umassmed.edu/ccts/education or 
tuftsctsi.org.
Baystate offers several training and career development opportunities for residents, 
fellows, and junior investigators. 














Number of years at Baystate: 8.5
What research training do you have? Masters in Clinical and 
Translational Research from Tufts, Mentorship from the IHDPS
What got you interested in research overall? I wanted 
to teach the residents evidence-based medicine, but 
many of the things that I thought were "right" in terms of 
care of patients, had little evidence (and conversely, many 
of the things we do regularly, also have little evidence). 
Research is a way of getting at the "truth" and what is right 
– and demonstrating "right" with science, rather than with 
persuasion. 
What is your area of research? I study the use of Shared 
Decision-Making in the Emergency Department – specifically 
whether we can use Shared Decision-Making to decrease 
advanced imaging and improve patients' experiences.
How do you see your research improving care for patients?  
In my newest study, we have the potential to decrease young 
patients' exposure to ionizing radiation, which will decrease 
future cancer incidence. This is obviously important for 
peoples' health in the long term. But using Shared Decision-
Making has the potential to improve short-term health too. 
By creating an environment where patients see themselves 
as part of the team and full players, we have the potential to 
improve adherence and trust within the system, which can 
improve health and well-being in the short term, too. 
What have been some of your favorite research projects 
to date that you have organized/participated in? In my 
qualitative projects, I get to interview doctors and patients – 
this is always a lot of fun. 
Do you have any awards? Baystate gave me the New 
Investigator Award in 2017. And this past winter I won for my 
age division in a slalom race in Vermont – there were only 
two of us, and we both fell, but I think I hiked back through the 
gates faster...
What do you like most about your job? I am very lucky to 
get to spend so much of my time on research. I love working 
clinically, but I get to spend my other days trying to find ways 
to improve the care we provide – and then designing studies 
to test whether my ideas work. It takes a lot of time, but I get 
to work with great people. Plus, sometimes the evidence 
suggests I'm right, so that's nice. (Nothing is ever "proven," 
though – so I never really "prove" that I'm right.)
What do you do to unwind outside of work? When I'm not 
playing/coaching soccer with my kids, I'm downhill mountain 
biking (summer/fall) or skiing. If you'd like to try downhill 
mountain biking with me, just let me know! We can meet at 
Berkshire East and talk study design on the lifts. 
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Dr. Schoenfeld and her family.
Lauren Westafer, DO, MPH, MS
